NCT05377372 Early Life Exposures Among Children With Sickle Cell Disease
| NCT ID | NCT05377372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-08-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being conducted to determine the relationship between early childhood exposures, such as Adverse Childhood Experiences, Social Determinants of Health and nutrition/breastfeeding, among children with sickle cell disease, and behavioral interventions aimed to reshape psychological resilience and lifestyle factors towards positive health outcomes.
Eligibility Criteria
Inclusion Criteria: * mother of infant with sickle cell disease * resides within the city of Birmingham, Alabama or in close proximity Exclusion Criteria: * prescribed teratogenic medications * no/limited internet access
Contact & Investigator
Brandi M Pernell, DNP, MSPH
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT05377372 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05377372 currently recruiting?
Yes, NCT05377372 is actively recruiting participants. Contact the research team at brandimcclain@uabmc.edu for enrollment information.
Where is the NCT05377372 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT05377372 clinical trial?
NCT05377372 is sponsored by University of Alabama at Birmingham. The principal investigator is Brandi M Pernell, DNP, MSPH at University of Alabama at Birmingham. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.